[Clinical development of oral chemotherapeutic agents for advanced gastric cancer].


5-fluorouracil (5-FU) has been the mainstay of systemic therapy since its initial development 50 years ago for gastrointestinal cancer. In Japan, the development of orally administered fluoropyrimidines that maintain or improve the effectiveness of intravenous 5-FU, has been advanced. In the JCOG9912 trial, S-1 demonstrated significant non-inferiority to 5… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics